Table 4 IPD-only and IPD and aggregate network results for patients losing ≥10 and ≥ 15 ETDRS letters

IPD-only network Comparison

Covariable adjustment

Model

OR

95% Crl

OR

95% Crl

IVT-AFL vs laser

None

Fixed

0.06^a

0.02–0.12

0.04^a

0.01–0.112

Random

0.11^a

0.01–0.29

0.22^a

0.00–0.28

Common (baseline BCVA)

Fixed

0.06^a

0.02–0.12

0.04^a

0.00–0.11

Random

0.19^a

0.01–0.27

0.07^a

0.00–0.24

Treatment-specific

Fixed

0.05^a

0.02–0.11

0.02^a

0.00–0.08

Random

0.08^a

0.01–0.24

0.04^a

0.00–0.16

IVT-AFL vs ranibizumab 0.5 mg PRN

None

Fixed

0.37

0.07–1.22

0.51

0.02–2.51

Random

92.49

0.01–8.70

278,400.00

0.00–39.31

Common (baseline BCVA)

Fixed

0.37

0.07–1.24

0.47

0.02–2.34

Random

483.00

0.01–6.20

825.00

0.00–22.22

Treatment-specific

Fixed

0.51

0.07–2.07

0.45

0.00–2.59

Random

9.28

0.01–7.53

300.00

0.00–15.68

IVT-AFL vs ranibizumab 0.5 mg PRN + laser

None

Fixed

0.17^a

0.04–0.44

0.23^a

0.02–0.91

Random

6.74

0.01–2.11

74.93

0.00–7.32

Common (baseline BCVA)

Fixed

0.18^a

0.04–0.47

0.20^a

0.02–0.81

Random

12.89

0.01–1.75

11.07

0.00–5.17

Treatment-specific

Fixed

0.18^a

0.04–0.51

0.13^a

0.00–0.65

Random

3.38

0.01–1.89

5.42

0.00–3.04

IPD and aggregate network

Comparison

Covariable adjustment

Model

OR

95% Crl

OR

95% Crl

IVT-AFL 2q8 vs laser

None

Fixed

0.06^a

0.02–0.12

0.04^a

0.00–0.12

Random

0.06^a

0.02–0.14

0.04^a

0.00–0.14

Common (baseline BCVA)

Fixed

0.06^a

0.02–0.12

0.04^a

0.00–0.11

Random

0.06^a

0.02–0.14

0.04^a

0.00–0.13

IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN

None

Fixed

0.24^a

0.07–0.60

0.31

0.02–1.15

Random

0.25^a

0.05–0.73

0.36

0.02–1.49

Common (baseline BCVA)

Fixed

0.24^a

0.07–0.59

0.28

0.02–1.05

Random

0.25^a

0.05–0.74

0.33

0.02–1.39

IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN + laser

None

Fixed

0.14^a

0.04–0.33

0.11^a

0.01–0.37

Random

0.15^a

0.03–0.41

0.13^a

0.01–0.47

Common (baseline BCVA)

Fixed

0.14^a

0.04–0.33

0.10^a

0.01–0.34

Random

0.15^a

0.03–0.41

0.11^a

0.01–0.43

IVT-AFL 2q8 vs ranibizumab 0.5 mg T&E

None

Fixed

0.15^a

0.01–0.75

0.33

0.00–1.94

Random

0.19^a

0.00–0.96

0.81

0.00–3.00

Common (baseline BCVA)

Fixed

0.15^a

0.00–0.73

0.30

0.00–1.74

Random

0.21^a

0.00–0.97

0.54

0.00–2.67

IVT-AFL 2q8 vs ranibizumab 0.5 mg T&E + laser

None

Fixed

222,500.00

0.03–607.2

201,200.00

0.02–671.3

Random

325,000.00

0.02–589.9

130,000.00

0.01–751.0

Common (baseline BCVA)

Fixed

470,400.00

0.03–555.1

3,311,000.00

0.02–592.0

Random

662,700.00

0.02–622.8

2,877,000.00

0.01–775.5